Laboratory Corporation of America® Holdings Announces 2015 First Quarter Results and Raises 2015 Adjusted EPS Guidance

Q1 Net revenue of $1.8 billion , up 24% over last year Q1 Diluted EPS of $0.01 ; Q1 Adjusted EPS of $1.73 , up 15% over last year 2015 Adjusted EPS guidance raised to $7.55 - $7.90 , compared to $6.80 in 2014 BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 27, 2015-- Laboratory Corporation of America ®

Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers

BRCA Share™ is a novel public-private initiative designed to enhance the clarity and quality of patient testing MADISON, N.J. and PARIS and BURLINGTON, N.C. , April 21, 2015 /PRNewswire/ --  Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm,

Bode Technology Supports Identification of Missing Persons in Cyprus Using DNA

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 9, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (LH: NYSE) today announced that its wholly-owned subsidiary Bode Cellmark Forensics (Bode Cellmark), a member of the LabCorp Specialty Testing Group , is cooperating with the Committee on

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Presents New Findings on HIV-1 and HCV Antiviral Drug Resistance at the 2015 Conference on Retroviruses and Opportunistic Infections

State of the art genetic and cell-based assays enable comprehensive characterization of resistance to new drugs and new drug classes BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 12, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that Monogram Biosciences,

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of March 12, 2015 to September 11, 2015 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp Contributes to Clinical Research Collaborations Directed at Advancing Treatment of Breast Cancer and Viral Hepatitis

Studies Promote Personalized Medicine and Advance Public Health Initiatives BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 4, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today highlighted clinical research efforts in oncology and viral hepatitis that demonstrate its

LabCorp is Scheduled to Present at the Barclays Capital 2015 Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 3, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the Barclays Capital 2015 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 10, 2015 at 8:30 AM (Eastern

Laboratory Corporation of America® Holdings Announces 2014 Fourth Quarter and Full Year Results and Provides 2015 Guidance

Strong Q4 volume drives sales of $1.5 billion Diluted Q4 EPS of $1.39 ; Adjusted Q4 EPS of $1.65 Q4 Operating Cash Flow of approximately $214 million Q4 Free Cash Flow of approximately $167 million Announces Project LaunchPad, its enterprise-wide business process improvement initiative 2015

LabCorp Completes Acquisition of Covance

Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 19, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of